1. US Library of Medicine. Genetics Home Reference: spinal muscular atrophy. 2020. http://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy. Accessed 19 Apr 2021.
2. Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14(4):214–24.
3. Brakemeier S, Stolte B, Thimm A, et al. Assessment of bulbar function in adult patients with 5q-SMA Type 2 and 3 under treatment with nusinersen. Brain Sci. 2021;11(9):1244.
4. Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2019;12(Cd006281):1–46.
5. Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;1(Cd006282):1–97.